Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States - 16/05/19
, Alexandra Chirilov, BS c, Felix Hey, BA d, Isabelle Gilloteau, MSc b, David Cella, PhD eAbstract |
Background |
Psoriasis Area and Severity Index (PASI) response rates have been the benchmark for evaluating treatment efficacy in trials involving moderate-to-severe psoriasis.
Objective |
To understand how dermatologists assess biologics and which trade-off rules they apply when planning psoriasis treatment.
Methods |
Two online surveys of 130 and 129 US dermatologists (surveys 1 and 2, respectively) were conducted with use of direct and indirect elicitation via discrete choice experiment. Respondents were asked to choose hypothetical biologics on the basis of 6 attributes (a ≥75% reduction from baseline in PASI score or a ≥90% reduction from baseline in PASI score, infection risk, dosing frequency, and 3 patient-reported outcomes [PROs] [relief of depression, relief of itching, and impact on usual activities]).
Results |
Most dermatologists (74% in survey 1 and 76% in survey 2) reported using both PASI and PROs when selecting a biologic. PASI response rate was the most important attribute (35%-38% of overall decision weight), whereas combined PRO attributes had similar importance (36% of decision weight). Infection risk and dosing frequency influenced the decision to a lesser extent.
Limitations |
Potential bias in considering 3 PROs versus 1 PASI rate and 1 safety attribute.
Conclusion |
PASI is most important for dermatologists selecting biologics, but PROs are also considered, especially when PASI response rate is similar between treatments. PRO data should be collected in trials involving moderate-to-severe psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : biologics, patient-reported outcomes, psoriasis, Psoriasis Area and Severity Index, treatment decision making
Abbreviations used : HRQoL, PASI, PASI 75, PASI 90, PRO, SoP
Plan
| Funding sources: Supported by Novartis AG. |
|
| Disclosure: Dr Feldman has received research, speaking, and/or consulting support from Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Eli Lilly and Company, Merck, Novartis, and Sun Pharma. Dr Regnier and Ms. Gilloteau are employees of and own stock in Novartis AG. Ms Chirilov and Mr Hey are employees of GfK SE and Ipsos SA, respectively, which received funding for this study from Novartis. Dr Cella has received consulting honoraria from Novartis and research grants to his institution from Novartis. |
|
| Reprints not available from the authors. |
Vol 80 - N° 6
P. 1650-1657 - juin 2019 Retour au numéro
Article précédent
- Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
- Makenzie L. Hawkins, Matthew J. Rioth, Megan M. Eguchi, Myles Cockburn
- Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013
- Anagha Bangalore Kumar, Elizabeth K. Blixt, Lisa A. Drage, Rokea A. el-Azhary, David A. Wetter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?